{"id":"mk-4830","safety":{"commonSideEffects":[{"effect":"Anaemia","drugRate":"55.7%","placeboRate":"","totalAtRisk":79,"totalAffected":44,"trialsReporting":1},{"effect":"Alopecia","drugRate":"44.3%","placeboRate":"","totalAtRisk":79,"totalAffected":35,"trialsReporting":1},{"effect":"Nausea","drugRate":"38.0%","placeboRate":"","totalAtRisk":79,"totalAffected":30,"trialsReporting":1},{"effect":"Constipation","drugRate":"36.7%","placeboRate":"","totalAtRisk":79,"totalAffected":29,"trialsReporting":1},{"effect":"Neutropenia","drugRate":"26.6%","placeboRate":"","totalAtRisk":79,"totalAffected":21,"trialsReporting":1},{"effect":"Fatigue","drugRate":"25.3%","placeboRate":"","totalAtRisk":79,"totalAffected":20,"trialsReporting":1},{"effect":"Neuropathy peripheral","drugRate":"25.3%","placeboRate":"","totalAtRisk":79,"totalAffected":20,"trialsReporting":1},{"effect":"Abdominal pain","drugRate":"24.1%","placeboRate":"","totalAtRisk":79,"totalAffected":19,"trialsReporting":1},{"effect":"Asthenia","drugRate":"20.3%","placeboRate":"","totalAtRisk":79,"totalAffected":16,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"19.0%","placeboRate":"","totalAtRisk":79,"totalAffected":15,"trialsReporting":1},{"effect":"Myalgia","drugRate":"19.0%","placeboRate":"","totalAtRisk":79,"totalAffected":15,"trialsReporting":1},{"effect":"Rash","drugRate":"19.0%","placeboRate":"","totalAtRisk":79,"totalAffected":15,"trialsReporting":1},{"effect":"Leukopenia","drugRate":"17.7%","placeboRate":"","totalAtRisk":79,"totalAffected":14,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"17.7%","placeboRate":"","totalAtRisk":79,"totalAffected":14,"trialsReporting":1},{"effect":"Procedural pain","drugRate":"16.5%","placeboRate":"","totalAtRisk":79,"totalAffected":13,"trialsReporting":1},{"effect":"Thrombocytopenia","drugRate":"15.2%","placeboRate":"","totalAtRisk":79,"totalAffected":12,"trialsReporting":1},{"effect":"Hypokalaemia","drugRate":"15.2%","placeboRate":"","totalAtRisk":79,"totalAffected":12,"trialsReporting":1},{"effect":"Vomiting","drugRate":"13.9%","placeboRate":"","totalAtRisk":79,"totalAffected":11,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"13.9%","placeboRate":"","totalAtRisk":79,"totalAffected":11,"trialsReporting":1},{"effect":"Neutrophil count decreased","drugRate":"13.9%","placeboRate":"","totalAtRisk":79,"totalAffected":11,"trialsReporting":1},{"effect":"Pruritus","drugRate":"12.7%","placeboRate":"","totalAtRisk":79,"totalAffected":10,"trialsReporting":1},{"effect":"Hypothyroidism","drugRate":"11.4%","placeboRate":"","totalAtRisk":79,"totalAffected":9,"trialsReporting":1},{"effect":"Alanine aminotransferase increased","drugRate":"11.4%","placeboRate":"","totalAtRisk":79,"totalAffected":9,"trialsReporting":1},{"effect":"Decreased appetite","drugRate":"11.4%","placeboRate":"","totalAtRisk":79,"totalAffected":9,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"10.1%","placeboRate":"","totalAtRisk":79,"totalAffected":8,"trialsReporting":1},{"effect":"Aspartate aminotransferase increased","drugRate":"10.1%","placeboRate":"","totalAtRisk":79,"totalAffected":8,"trialsReporting":1},{"effect":"Platelet count decreased","drugRate":"10.1%","placeboRate":"","totalAtRisk":79,"totalAffected":8,"trialsReporting":1},{"effect":"Hypomagnesaemia","drugRate":"10.1%","placeboRate":"","totalAtRisk":79,"totalAffected":8,"trialsReporting":1},{"effect":"Gamma-glutamyltransferase increased","drugRate":"8.9%","placeboRate":"","totalAtRisk":79,"totalAffected":7,"trialsReporting":1},{"effect":"Headache","drugRate":"8.9%","placeboRate":"","totalAtRisk":79,"totalAffected":7,"trialsReporting":1},{"effect":"Paraesthesia","drugRate":"8.9%","placeboRate":"","totalAtRisk":79,"totalAffected":7,"trialsReporting":1},{"effect":"Weight decreased","drugRate":"7.6%","placeboRate":"","totalAtRisk":79,"totalAffected":6,"trialsReporting":1},{"effect":"White blood cell count decreased","drugRate":"7.6%","placeboRate":"","totalAtRisk":79,"totalAffected":6,"trialsReporting":1},{"effect":"Back pain","drugRate":"7.6%","placeboRate":"","totalAtRisk":79,"totalAffected":6,"trialsReporting":1},{"effect":"Dizziness","drugRate":"6.3%","placeboRate":"","totalAtRisk":79,"totalAffected":5,"trialsReporting":1},{"effect":"Dysgeusia","drugRate":"6.3%","placeboRate":"","totalAtRisk":79,"totalAffected":5,"trialsReporting":1},{"effect":"Peripheral sensory neuropathy","drugRate":"6.3%","placeboRate":"","totalAtRisk":79,"totalAffected":5,"trialsReporting":1},{"effect":"Insomnia","drugRate":"6.3%","placeboRate":"","totalAtRisk":79,"totalAffected":5,"trialsReporting":1},{"effect":"Hyperthyroidism","drugRate":"5.1%","placeboRate":"","totalAtRisk":79,"totalAffected":4,"trialsReporting":1},{"effect":"Oedema peripheral","drugRate":"5.1%","placeboRate":"","totalAtRisk":79,"totalAffected":4,"trialsReporting":1},{"effect":"COVID-19","drugRate":"5.1%","placeboRate":"","totalAtRisk":79,"totalAffected":4,"trialsReporting":1},{"effect":"Lymphocyte count decreased","drugRate":"5.1%","placeboRate":"","totalAtRisk":79,"totalAffected":4,"trialsReporting":1},{"effect":"Hyperglycaemia","drugRate":"5.1%","placeboRate":"","totalAtRisk":79,"totalAffected":4,"trialsReporting":1},{"effect":"Hypoalbuminaemia","drugRate":"5.1%","placeboRate":"","totalAtRisk":79,"totalAffected":4,"trialsReporting":1},{"effect":"Pain in extremity","drugRate":"5.1%","placeboRate":"","totalAtRisk":79,"totalAffected":4,"trialsReporting":1},{"effect":"Neurotoxicity","drugRate":"5.1%","placeboRate":"","totalAtRisk":79,"totalAffected":4,"trialsReporting":1},{"effect":"Anxiety","drugRate":"5.1%","placeboRate":"","totalAtRisk":79,"totalAffected":4,"trialsReporting":1},{"effect":"Dyspnoea","drugRate":"5.1%","placeboRate":"","totalAtRisk":79,"totalAffected":4,"trialsReporting":1},{"effect":"Rash maculo-papular","drugRate":"5.1%","placeboRate":"","totalAtRisk":79,"totalAffected":4,"trialsReporting":1},{"effect":"Hypertension","drugRate":"5.1%","placeboRate":"","totalAtRisk":79,"totalAffected":4,"trialsReporting":1}]},"_chembl":null,"_fixedAt":"2026-03-30T17:56:13.304576","_dailymed":null,"_scrapedAt":"2026-03-28T03:39:08.468Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:52:05.086462+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_fixedFields":["pubmed(6)"],"trialDetails":[{"nctId":"NCT05319730","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":230},{"nctId":"NCT04938817","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-08-19","conditions":"Small Cell Lung Carcinoma","enrollment":110},{"nctId":"NCT04165070","phase":"PHASE1, PHASE2","title":"KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-19","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":450},{"nctId":"NCT04895722","phase":"PHASE2","title":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-25","conditions":"Colorectal Cancer","enrollment":302},{"nctId":"NCT05342636","phase":"PHASE1, PHASE2","title":"A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-27","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":90},{"nctId":"NCT04165083","phase":"PHASE2","title":"KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-19","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":102},{"nctId":"NCT04303169","phase":"PHASE1, PHASE2","title":"Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-06-26","conditions":"Melanoma","enrollment":146},{"nctId":"NCT03564691","phase":"PHASE1","title":"Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-11","conditions":"Neoplasms","enrollment":470},{"nctId":"NCT05446870","phase":"PHASE2","title":"Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-25","conditions":"High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma","enrollment":160},{"nctId":"NCT04626518","phase":"PHASE1, PHASE2","title":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-17","conditions":"Carcinoma, Renal Cell","enrollment":370},{"nctId":"NCT04924101","phase":"PHASE2","title":"Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-07-15","conditions":"Small Cell Lung Cancer","enrollment":126},{"nctId":"NCT04165096","phase":"PHASE2","title":"KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-01-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":128},{"nctId":"NCT06413095","phase":"EARLY_PHASE1","title":"PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS","status":"COMPLETED","sponsor":"Presage Biosciences","startDate":"2022-06-01","conditions":"Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"recentPublications":[{"date":"2024","pmid":"39193329","title":"Case report: Lichenoid eruption under immunotherapy with MK-4830 and pembrolizumab in a breast cancer patient.","journal":"Frontiers in pharmacology"},{"date":"2023 Dec","pmid":"37701986","title":"KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer.","journal":"Future oncology (London, England)"},{"date":"2023","pmid":"36968984","title":"A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report.","journal":"SAGE open medical case reports"},{"date":"2022 Sep 15","pmid":"36106403","title":"Correction: First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"date":"2022 Apr 14","pmid":"35419588","title":"Correction: First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["anti-immunoglobulin-like transcript 4 (ILT4)","anti-immunoglobulin-like transcript 4 (anti-ILT4)"],"phase":"phase_2","status":"active","brandName":"MK-4830","genericName":"MK-4830","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":12,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:52:05.086462+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}